Back to Top
  • Clinical OMICs is becoming Inside Precision Medicine in 2022!

    Driven by a rapid and exponentially growing market – one that is expected to be valued at more than $126 billion by 2025 – and our commitment to covering the full breadth of the revolutionary field of precision medicine, Clinical OMICs is becoming Inside Precision Medicine in 2022.


    Inside Precision Medicine will continue to deliver the critical, foundational coverage of Translational Research, Molecular Diagnostics, Informatics, Oncology, and Patient Care that subscribers rely on while expanding coverage into leading-edge, headline-driving topics like Payer and Regulatory issues, including insurance and reimbursement, regulatory review and approval, and data privacy and security.

Aims & Scope

Clinical OMICs is the leading media resource for researchers, pathologists, clinicians, and other professionals working to deliver on the promise of precision medicine. From sequencers and biomarkers to software and clinical decision support and everything in between, Clinical OMICs helps its readers stay current on the most critical research, tools, regulations, and applications affecting the practice of molecular pathology, the development of omics technologies and diagnostics, and the delivery of precision medicine.

Clinical OMICs is a must-have title for your institution – the only publication that brings together into one premier resource the full scope of precision medicine to meet the information needs of researchers, academics, and industry professionals. A subscription provides immediate access to all new content, as well as at least five full years’ of archive content from Clinical OMICs.

Clinical OMICs coverage includes:

  • Translational Research
    • Biomarkers
    • Proteomics
    • Metabolomics
    • Microbiome
    • Genome-Wide Association Studies (GWAS)
  • Molecular Diagnostics
    • Oncology
    • Pharmacogenomics
    • NIPT (Non-Invasive Prenatal Testing)
    • Point of Care Diagnostics
    • CRISPR
  • Informatics
    • Big Data
    • Health Data Integration
    • Population Health
    • Polygenic Risk Scores
    • Artificial Intelligence
  • Oncology
    • Immunotherapy
    • Targeted Therapies
    • Diagnostic/Therapy Co-Development
    • Digital Pathology
    • Therapy/Disease Recurrence Montoring
  • Patient Care
    • Clinical Decision Support
    • Gene Therapy
    • Rare Diseases
    • Genetic Counseling
    • Wellness
  • Payer/Regulatory
    • Private/Public Insurance
    • FDA
    • Clinical Trials
    • Data Privacy and Security
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.